Vir Biotechnology, Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 24/100
What the filing says
Vir Biotechnology hired Aziz Sawaf as EVP and Chief Financial Officer effective September 1, 2026, with an annualized base salary of $520,000, a $150,000 sign-on bonus (split over two years), and equity grants of 150,000 stock options and 75,000 RSUs vesting over four years. Critically, employment start is contingent on the closing of the pending acquisition of Theravance Biopharma by Zymeworks Inc. and termination of Sawaf's Theravance employment. Sawaf is eligible for a 45% annual bonus and severance benefits under Vir's Change in Control and Severance Benefit Plan. No material financial impact is disclosed.
Why this rating
CFO hire is standard executive staffing. Equity package (~$7.5M at grant, estimated) represents ~1.1% of market cap—material but routine for biotech CFO. Deal contingency creates execution risk but is external to Vir's operations.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.